Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

Summary

This partially randomized phase II trial is studying how well giving bicalutamide together with RO4929097 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bicalutamide together with RO4929097 may be an effective treatment for prostate cancer

Timeline

Start

2010-08

Primary completion

2012-08

Completion

2012-11

Drugs

Indications